Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 251Head & Neck 132Thoracic 46Gynecologic 11Tumor-Agnostic 9Breast 8Genitourinary 5Sarcoma 4CNS 3Plasma cell 2Other solid neoplasm 2Other neoplasm 2Dermatologic 2

Conditions

Multiple Myeloma 2Neoplasms 1

Interventions

Dexamethasone 373Lenalidomide 206Bortezomib 200Cyclophosphamide 178Melphalan 135Calcium Dobesilate 120daratumumab 107pomalidomide 74carfilzomib 74fludarabine phosphate 71Peripheral Blood Stem Cell Transplantation 66Thalidomide 57Filgrastim 57Mycophenolic Acid 56Busulfan 55Tacrolimus 48Granulocyte Colony-Stimulating Factor 47ixazomib 45fludarabine 45Whole-Body Irradiation 44dexamethasone acetate 36Cyclosporine 35isatuximab 34Etoposide 34Antilymphocyte Serum 32dexamethasone 21-phosphate 30elotuzumab 28auricularum 27Prednisone 27plerixafor 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Cetuximab × Plasma cell × Clear all
NCT01524978 2017-11-20

A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers

Hoffmann-La Roche

Phase 2 Completed
208 enrolled 26 charts
Plasma cell

Multiple Myeloma, Neoplasms

NCT00368121 2012-07-13

EMMA-1

University of Cologne

Phase 2 Terminated
13 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡